Introduction
Patients with type 2 diabetes mellitus (T2DM) have an increased risk of incident and recurrent cardiovascular Figure 1 . Risk of major vascular events with or without diabetes mellitus in patients with prior ischemic events, stable atherosclerosis, and multiple risk factors only in the REACH registry. Prior ischemic events were defined as prior myocardial infarction or stroke. Error bars indicate 95% confidence intervals. Abbreviations: CV, cardiovascular; REACH, REduction of Atherothrombosis for Continued Health. Reprinted from Bhatt DL et al. 5 Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis, JAMA. 2010;304:1350-1357 © (2010), with permission from the American Medical Association. All rights reserved.
low-density lipoprotein cholesterol with a potent statin, and platelet inhibition with aspirin therapy, can reduce recurrent cardiovascular risk in these patients. T2DM patients with additional cardiovascular risk factors are at high risk for incident ischemic events and statin therapy is also efficacious in this setting. As a result, there has been widespread clinical implementation of statin therapy in patients with T2DM. In contrast, the additional benefit of aspirin therapy in patients without established cardiovascular disease, even those with T2DM, awaits definitive results. One important arena in which decisions and strategies for implementation of these therapies are crucial is within cardiovascular outcomes trials studying new therapies in patients with T2DM. A tested novel cardioprotective therapy is likely to be judged in the context of the trial patients' background treatment. In this review, we provide the data in support of, and our recommendations for, the use of statins and aspirin for the prevention of cardiovascular (CV) events in high-risk patients with T2DM. Current guidelines separate patients into those with either established cardiovascular disease (secondary prevention) and those patients at high-risk for cardiovascular disease as a result of multiple risk factors (primary prevention) when discussing the evidence for these cardiovascular preventive therapies, and we discuss these therapies in that context. In particular, we review the role of statins and aspirin for primary prevention therapy in high-risk patients with diabetes, considering recent results, potential controversy, and misconceptions of the benefits and risks of these medications in diabetic patients without a prior cardiovascular event. 1 -3 We conclude with a summary of the landscape of background therapy in contemporary cardiovascular outcomes trials of patients with T2DM, including trial recommendations for statin and aspirin treatment, highlighting the large ongoing SAVOR-TIMI 53 trial as an example.
Why Is Cardiovascular Risk Reduction Important in Diabetes?
Patients with T2DM are at 2-to 4-times increased risk of CV events compared with those without T2DM. 4, 5 In patients older than 65 years, the primary cause of death in 2 out of 3 diabetic patients is coronary heart disease, followed by stroke in 1 out of 6. 6 The risk of major vascular events may be lowered with lifestyle changes and medical therapy, but nevertheless the emphasis on prevention is important because a diabetic patient's first vascular event may be fatal. 7 Patients with established atherothrombosis (occlusive vascular disease) have a high risk of recurrent major vascular events (myocardial infarction [MI], stroke, or CV death). 5 The highest risk group is those with prior ischemic events, followed by those with stable atherosclerosis, and those with T2DM and multiple risk factors without established cardiovascular disease (CVD). Patients with T2DM are at higher risk within all of these disease state categories ( Figure 1 ).
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Statin Therapy Secondary Prevention With Statins
Diabetic patients commonly have dyslipidemia. 8 Characteristic abnormalities in the lipid profile in T2DM include elevated triglycerides and apolipoprotein B, increased lowdensity lipoprotein (LDL) cholesterol, very low-density lipoprotein cholesterol (VLDL), and free fatty acids, as well as decreased atheroprotective high-density lipoprotein (HDL) cholesterol levels. 4,8 -10 The lipid abnormalities that develop in T2DM promote atherogenesis and are strongly related to CVD risk. 4, 11 Therefore, dyslipidemia is an important therapeutic target.
Metabolic and lipid abnormalities improve with weight loss, exercise, smoking cessation, and dietary modification. We emphasize counseling of patients toward achieving these therapeutic lifestyle modifications (see What Do the Guidelines Say?). Just as important is pharmacologic treatment with statins that have proven benefit in decreasing CVD risk in T2DM, especially in those patients with established atherosclerosis 11 ( Figure 2 ). Statins are safe, very well tolerated, and highly effective in reducing LDL cholesterol by increasing LDL clearance and decreasing VLDL secretion. What Do the Guidelines Say? Current guidelines 14 -17 recommend lifestyle modification to lower lipid levels by focusing on:
• Reducing saturated fat, trans fat, and cholesterol intake; • Increasing omega-3 fatty acid, viscous fiber, and plant oil intake; • Weight loss if indicated;
• Increased physical activity.
The guidelines also recommend statin therapy for secondary prevention of CVD in diabetic patients with established atherosclerosis regardless of baseline lipid levels.
14 - 17 The primary goal of therapy is to achieve an LDL cholesterol (LDL-C) <100 mg/dL (<2.6 mmol/L) and ideally <70 mg/dL (<1.8 mmol/L) using higher-dose statins (Table 1) .
When lipid levels do not meet these targets on maximally tolerated statin therapy, the guidelines provide an alternative acceptable goal for a reduction in LDL-C of at least 30% below baseline. In addition, desirable non-HDL-C levels in patients with T2DM are <130 mg/dL (<3.3 mmol/L) and ideally <100 mg/dL (<2.6 mmol/L) (or triglyceride levels <150 mg/dL (<1.7 mmol/L) and HDL cholesterol >40 mg/dL (>1 mmol/L) in men or >50mg/dL (>1.3 mmol/L) in women) and apolipoprotein-B (Apo-B) <100 mg/dL (1.0 g/L) and ideally <80 mg/dL (0.80 g/L). Nevertheless, LDL values remain the preferred lipid-lowering targets with statins.
Primary Prevention With Statins
The benefits of statin therapy to prevent vascular events or vascular death in high-risk diabetic men and women without established CVD are also clear. 18 -21 that studied statins for primary prevention of CVD incorporated into the CTT meta-analysis. 11 Many trials enrolled a combination of diabetic patients with and without established atherosclerosis, but CARDS was one of the few trials that enrolled exclusively diabetic patients without established atherosclerosis ( Figure 3) . Overall, the CTT meta-analysis found that the onset of a first major vascular event was reduced by 27% ( Figure 4 A potential remaining controversy in the use of statin therapy for primary prevention in T2DM, is whether there is any additional benefit derived from a statin if a diabetic patient has already reached recommended target lipid levels (ie, <100 mg/dL or <2.6 mmol/L) without administration of a statin. The CTT Collaboration meta-analysis included over 2700 patients with T2DM whose baseline LDL cholesterol concentrations were already <100 mg/dL (<2.6 mmol/l).
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In diabetic patients who started with an LDL <100 mg/dL (<2.6 mmol/L), a 32% reduction of serious vascular events for every 40 mg/dL (1 mmol/L) reduction in LDL achieved with statins ( Figure 5 : events [%] in control arm, 12.2%, vs events in statin arm, 9.8%; RR 0.68, 99% CI 0.45-1.03; P = 0.02) was observed. In other words, CTT demonstrated a decrease from 12.2% events per year to 9.8% per year with statins; a number needed to treat of 42 patients over 5 years to prevent 1 additional event. The CTT investigators concluded that a statin should be recommended for all patients with T2DM at risk of CVD, regardless of baseline lipid levels. (Table 1 ).
What Do the Guidelines
14 - 17 The primary goal of therapy is to achieve an LDL cholesterol (LDL-C) <100 mg/dL (<2.6 mmol/L) and ideally <70 mg/dL (<1.8 mmol/L) using higher dose statins. When lipid levels do not meet these targets on maximally tolerated statin therapy, the guidelines again provide an alternative acceptable goal for an LDL-C reduction of at least 30%. 14 -17,22 -24 The health benefit translates into 36 fewer (95% CI, 23-49) serious vascular events for every 1000 diabetic patients without established CVD who achieve an LDL cholesterol reduction of 40 mg/dL (1 mmol/L) with statin therapy over 5 years; additional reductions achieved in LDL cholesterol would translate into even more prevented events.
High-risk individuals, originally determined from results of the Framingham Heart Study, 25 are those without established CVD with an estimated 10% risk of developing an incident CV event over the ensuing 10 years due to the presence of multiple risk factors. This group includes diabetic men ≥50 years or women ≥60 years with at least 1 additional CVD risk factor (smoking, hypertension, hyperlipidemia, albuminuria, or family history of CVD). Therefore, we recommend these high-risk diabetic patients receive statin therapy for primary prevention of CV events regardless of baseline lipid levels. Figure 6 ). 
Aspirin Therapy Secondary Prevention With Aspirin
What Do the Guidelines Say?
Current guidelines recommend aspirin therapy (75-162 mg/d) for secondary prevention of recurrent CV events in diabetic patients with established coronary artery disease, cerebrovascular disease, and symptomatic peripheral arterial disease (Table 1 ).
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Primary Prevention With Aspirin
Aspirin may also prevent a first vascular event in patients with T2DM and multiple risk factors without established atherosclerosis; however, definitive evidence of its benefit remains to be demonstrated. Among 4000 diabetic men and women without CVD studied in the ATT Collaboration, aspirin therapy lowered the risk of serious vascular events by 12% (events [%] in control arm, 0.57% per year, vs events in aspirin arm, 0.50% per year; RR 0.88, 95% CI, 0.82-0.94; P = 0.0001; treating 1429 patients for 1 year will result in 1 fewer major vascular event). 27 Cardiovascular risk reduction was driven primarily by reduction in nonfatal MI. More recent findings from the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial, a factorial randomized placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease (PAD), failed to demonstrate the efficacy of aspirin therapy for primary prevention of incident CV events. 28 When the results of this study were incorporated into an updated meta-analysis of the effect of aspirin for primary prevention of vascular and nonvascular outcomes, the totality of evidence did not support the routine use of aspirin prophylaxis in patients without established CVD for the prevention of CV death (events in control arm, 4.0 per 1000 person-years, vs events in aspirin arm, 3.9 per 1000 person-years; OR, 0.99; 95% CI, 0.85-1.15), despite important reductions in nonfatal MI (events in control arm,
patients for 1 year will result in 1 fewer nonfatal MI). 2 In addition, an observed increased risk of major bleeding (defined as fatal bleeding, bleeding requiring hospitalization and/or transfusion, cerebrovascular, retinal, or major organ bleeding, or study-defined major bleeding regardless of source) was found to be associated with aspirin use (events in control arm, 7.4 per 1000 person-years, vs events in aspirin arm, 9.7 per 1000 person-years; OR, 1.31; 95% CI, 1.14-1.50; treating 73 patients for 1 year will result in 1 additional major bleeding event). One hypothesis for why a diminished improvement in CV events was observed in more recent aspirin trials may be the observed higher rate of statin use in these primary prevention trials, underscoring again their importance in diminishing CV risk in these patients.
POPADAD is currently the only trial to study aspirin for primary prevention exclusively in patients with diabetes in the current era; however, patients enrolled in this trial were relatively low-risk patients with type 1 DM or T2DM over the age of 40 with asymptomatic PAD and no other risk factor enrichment criteria. In addition, the POPADAD trial was not powered to demonstrate a modest effect of aspirin therapy in this population because the investigators designed the study with an anticipated annual primary endpoint event rate of 8%, but observed an annual event rate of only 2.3%. 28 Important trials are ongoing to determine the contemporary benefits of aspirin for primary prevention of cardiovascular events in diabetic patients. 29 Until the results of these studies are reported, it is reasonable to consider aspirin for patients with T2DM and multiple risk factors who are not at high risk for bleeding. Although the absolute benefit may be small for aspirin in primary prevention, the effect is very meaningful on a population-wide perspective because millions of patients with T2DM have multiple risk factors without established atherosclerosis. In addition, patients with diabetes who have more than 1 risk factor have an even higher baseline risk of incident CV events than the event rates reported in aspirin primary prevention studies and may derive even greater benefit from aspirin. 25 If treating physicians and/or patients are concerned about the potential risk of gastrointestinal (GI) bleeding, then concurrent aspirin use with proton-pump inhibitors has been shown to decrease the risk of first or recurrent aspirin-related GI bleeding. 30, 31 In summary, available data suggest that there may not be a net clinical benefit in favor of routine aspirin for the prevention of a first major vascular event in T2DM patients, but studies are still ongoing to determine the benefit of aspirin in diabetic patients with multiple risk factors.
What Do the Guidelines Say?
Current guidelines encourage consideration of aspirin (75-162 mg/d) for the primary prevention of a first vascular event in high-risk men and women with T2DM (Table 1) . Specifically, aspirin is appropriate in diabetic men aged ≥50 years or women aged ≥60 years with at least 1 additional CVD risk factor who are at low risk for major bleeding (ie, no history of previous GI bleeding or peptic ulcer disease or concurrent use of other medications that increase bleeding risk, such as warfarin). 14 -16,22,23,32 These criteria fit the description of the high-risk patients with T2DM, and therefore we recommend that appropriately selected patients at low risk for bleeding be treated with low-dose aspirin for the primary prevention of CV events.
What Are the Recommendations for, and Use of, Statin and Aspirin Therapy in Contemporary Cardiovascular Outcomes Trials Studying Patients With T2DM?
A review of published contemporary major cardiovascular outcomes trials, cohort studies, and design papers in patients with T2DM revealed that the vast majority of studies stipulated that background risk-factor preventive care be consistent with current guideline recommendations at the time of conduct. 33 -46 The baseline use of statin and aspirin therapy, along with angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) use, and the concomitant use of antidiabetic medications within these studies are presented in Table 2 . Only 1 study reported in their main publication or methods paper that statin and aspirin therapy was expected to be prescribed to all participants unless contraindicated. 38 Nevertheless, even under these ideal circumstances, contemporary cardiovascular outcomes trials studying secondary prevention in patients with T2DM enroll cohorts with approximately 75% statin use at baseline and approximately 60% use in mixed primary/secondary prevention cohorts, achieving only slight improvement over the course of the observation period. Regarding aspirin therapy, a similar ceiling is seen; with baseline use of 50% to 70% in most trials that enroll mixed primary/secondary prevention cohorts from diverse international regions with varied access to background care.
In ongoing trials, the guideline-defined high-risk diabetic patient groups who either have established CVD (secondary prevention) or multiple risk factors (primary prevention), parallel those of patients enrolled in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. 47 SAVOR-TIMI 53 is a phase 4, randomized, double-blind, placebo-controlled trial of 16,500 subjects from 26 countries, designed to evaluate the cardiovascular efficacy and safety of saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, for the longterm treatment of T2DM. Eligible patients who are either antidiabetic treatment-naive or on any other background therapy are randomized 1:1 to saxagliptin 5 mg daily or matching placebo, stratified by the presence or absence of a history of established CVD. The objectives of the trial are to demonstrate the CV efficacy of a novel antidiabetic therapy in conjunction with other cardioprotective therapies in patients with T2DM, such as statins, aspirin, and blood pressure control medications. The primary endpoint is the composite of CV death, nonfatal MI, or nonfatal ischemic stroke. Within the primary prevention cohort of SAVOR-TIMI 53, all subjects with T2DM without established CVD had at least 2 additional risk factors present at enrollment, increasing their risk for an incident CV event. Therefore, the aforementioned recommendations for the use of statin and aspirin therapy in patients with T2DM were provided to the investigators of the SAVOR-TIMI 53 trial, which enrolled 16,500 patients with T2DM with, or at risk of, atherothrombosis and who generally meet the threshold for these impactful preventive cardiovascular therapies. 
Conclusion
Statin and aspirin therapy protect a wide range of patients with T2DM with established, or at high risk of developing, atherothrombosis. These therapies, along with diet, exercise, and blood pressure control with medications such as ACE inhibitors, are currently considered the cornerstones of secondary and, in appropriately selected patients, primary cardiovascular therapy in high-risk diabetic patients. There remains considerable controversy regarding the balance of cardiovascular efficacy and potential bleeding with aspirin for primary prevention among younger or low-risk patients with T2DM. The results of ongoing large randomized clinical trials are therefore eagerly awaited to provide insight into this group of patients. In appropriately selected diabetic patients with multiple risk factors, the risk for incident or recurrent CV events is considered high enough to justify the protective therapy statins and aspirin afford.
